1. Home
  2. CAPR vs OPRT Comparison

CAPR vs OPRT Comparison

Compare CAPR & OPRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • OPRT
  • Stock Information
  • Founded
  • CAPR 2005
  • OPRT 2005
  • Country
  • CAPR United States
  • OPRT United States
  • Employees
  • CAPR N/A
  • OPRT N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • OPRT Finance: Consumer Services
  • Sector
  • CAPR Health Care
  • OPRT Finance
  • Exchange
  • CAPR Nasdaq
  • OPRT Nasdaq
  • Market Cap
  • CAPR 322.7M
  • OPRT 298.8M
  • IPO Year
  • CAPR N/A
  • OPRT 2019
  • Fundamental
  • Price
  • CAPR $7.10
  • OPRT $6.00
  • Analyst Decision
  • CAPR Strong Buy
  • OPRT Hold
  • Analyst Count
  • CAPR 8
  • OPRT 2
  • Target Price
  • CAPR $24.75
  • OPRT $8.00
  • AVG Volume (30 Days)
  • CAPR 1.7M
  • OPRT 507.5K
  • Earning Date
  • CAPR 08-11-2025
  • OPRT 08-06-2025
  • Dividend Yield
  • CAPR N/A
  • OPRT N/A
  • EPS Growth
  • CAPR N/A
  • OPRT N/A
  • EPS
  • CAPR N/A
  • OPRT N/A
  • Revenue
  • CAPR $13,392,150.00
  • OPRT $724,757,000.00
  • Revenue This Year
  • CAPR $16.24
  • OPRT $28.27
  • Revenue Next Year
  • CAPR $328.11
  • OPRT $6.59
  • P/E Ratio
  • CAPR N/A
  • OPRT N/A
  • Revenue Growth
  • CAPR N/A
  • OPRT N/A
  • 52 Week Low
  • CAPR $3.98
  • OPRT $2.37
  • 52 Week High
  • CAPR $23.40
  • OPRT $9.25
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 42.24
  • OPRT 46.78
  • Support Level
  • CAPR $6.90
  • OPRT $5.51
  • Resistance Level
  • CAPR $8.00
  • OPRT $6.30
  • Average True Range (ATR)
  • CAPR 0.55
  • OPRT 0.34
  • MACD
  • CAPR -0.02
  • OPRT 0.00
  • Stochastic Oscillator
  • CAPR 7.91
  • OPRT 36.11

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About OPRT Oportun Financial Corporation

Oportun Financial Corp is engaged in providing financial services to people who either do not have a credit score or who may have a limited credit history. The company offers Personal Loans, Auto Loans, unsecured personal loans, and secured personal loans, and provides deposit accounts, debit card services, and other transaction services to its customers. Its product offerings include small-dollar, unsecured installment loans and other products and services.

Share on Social Networks: